Heat-treated, shelf-stable liquid nutritional compositions comprising whey protein and non-whey protein, and methods of producing and using these compositions. The compositions have a pH of from about 6.0 to about 8.0, a total protein content of at least about 6 g per 100 mL of the composition. The whey protein comprises or is provided by an ingredient that comprises heat-denaturable protein of which at least about 55% is present in a denatured state, and the non-whey protein comprises or consists of casein, or one or more non-dairy proteins, or casein and one or more non-dairy proteins.

The present technology relates to a nutritional formulation for administration to bariatric individuals. The nutritional formulation includes a multi-nutrients dosage unit; and a minerals dosage unit.

Disclosed herein is a dietary supplement containing alpha-glyceryl phosphoryl choline, phosphatidylserine, and an alkalizing agent, and its use in methods of maintaining or improving brain functions, such as mental focus, clarity, long-term memory, short-term memory, analytical reasoning, higher learning, mental processing, mental clarity, creativity, procrastination, willpower, reasoning, mood, retrieval/recall, learning gradient, and reaction time. The supplement can also be used in methods of treating or preventing cognitive dysfunction and dementia.

Disclosed herein is a dietary supplement containing alpha-glyceryl phosphoryl choline, phosphatidylserine, and an alkalizing agent, and its use in methods of maintaining or improving brain functions, such as mental focus, clarity, long-term memory, short-term memory, analytical reasoning, higher learning, mental processing, mental clarity, creativity, procrastination, willpower, reasoning, mood, retrieval/recall, learning gradient, and reaction time. The supplement can also be used in methods of treating or preventing cognitive dysfunction and dementia.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A carbonated, oral rehydration beverage that includes about 25-75 mEq/L of sodium, about 15-40 mEq/L of potassium, about 20-55 mEq/L of chloride, dextrose, and at least about 2.0 volumes of CO.sub.2. A method of treating or preventing dehydration is also provided.

A carbonated, oral rehydration beverage that includes about 25-75 mEq/L of sodium, about 15-40 mEq/L of potassium, about 20-55 mEq/L of chloride, dextrose, and at least about 2.0 volumes of CO.sub.2. A method of treating or preventing dehydration is also provided.

The present invention relates to novel nutritional compositions useful in the treatment of neoplastic diseases. More specifically, the present invention provides for nutritional composition comprising at least resistant starch, proteins and fats, that is able to retard the cancer growth reducing the inflammatory state of the patient and avoiding chronic weight loss.

The present invention relates to novel nutritional compositions useful in the treatment of neoplastic diseases. More specifically, the present invention provides for nutritional composition comprising at least resistant starch, proteins and fats, that is able to retard the cancer growth reducing the inflammatory state of the patient and avoiding chronic weight loss.